Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Experience with high-dose methotrexate therapy for malignant solid tumors]

K Kawai, T Shibata, E Azuma

    Gan to Kagaku Ryoho. Cancer & Chemotherapy
    |February 1, 1982
    PubMed
    Summary

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Lemierre syndrome complicated by bronchopleural fistula.

    Journal of postgraduate medicine·2023
    Same author

    Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study.

    Journal of viral hepatitis·2016
    Same author

    Pyrenolide D, a New Cytotoxic Fungal Metabolite from Pyrenophora teres.

    Bioscience, biotechnology, and biochemistry·2016
    Same author

    Triterpenoid biosynthesis in tissue cultures of Glycyrrhiza glabra var. glandulifera.

    Plant cell reports·2013
    Same author

    Efficacy of azithromycin in preventing lethal graft-versus-host disease.

    Clinical and experimental immunology·2013
    Same author

    The effect of azithromycin on the maturation and function of murine bone marrow-derived dendritic cells.

    Clinical and experimental immunology·2011

    High-dose methotrexate (MTX) therapy is a relatively safe treatment for malignant solid tumors, including osteogenic sarcomas, when closely monitored. Some patients with osteosarcoma showed no evidence of disease for over 18 months post-treatment.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • High-dose methotrexate (MTX) is an antineoplastic agent used in cancer chemotherapy.
    • Investigating the safety and efficacy of high-dose MTX in patients with malignant solid tumors is crucial.

    Observation:

    • Thirteen patients with malignant solid tumors, primarily osteogenic sarcomas, received high-dose MTX (50-400 mg/kg) over 72 cycles.
    • Eight osteosarcoma patients, six without initial metastatic lesions, were monitored.
    • Clinical efficacy was noted in some cases, particularly with intracranial tumors.

    Findings:

    • High-dose MTX therapy demonstrated relative safety with careful clinical surveillance.
    • Three out of eight osteosarcoma patients remained disease-free for 18-25 months post-therapy.
    • Clinical efficacy was observed in certain malignant solid tumors, including intracranial types.

    Related Experiment Videos

    Implications:

    • High-dose MTX therapy is a viable option for select malignant solid tumors, especially osteosarcomas.
    • Further research into dose-time relationships is recommended to optimize therapeutic efficacy.
    • Careful patient monitoring is essential for safe administration of high-dose MTX.